JP EN 中文

The Future of Medicine Shaped
by Cutting-Edge Cell Design Technology

The Research Institute for Cell Design Medical Science (RICeD) aims to become an international research and development center that successively creates seeds for the next-generation cell and gene therapies, through innovative cell design technologies, which are core strength of Yamaguchi University. RICeD also aims to promote the practical application of cutting-edge immunotherapy and genome medicine based on our innovative technologies, to develop treatments for intractable diseases such as cancer and genetic diseases, and to apply and verify these innovative therapies in companion animals. By creating an active cycle in which knowledge gained in humans and companion animals is fed back to each other, RICeD will endeavor to form a drug discovery ecosystem through the social implementation of the created technologies, contribute to local communities and foster human resources through the creation of industries, and extend the healthy lifespan of both humans and companion animals.

  • ALL
  • News
  • Thesis
  • Recruiting
*Report* Open Seminar of the Division of Advanced Genome Editing Therapy was held.

News

2025.03.28

*Report* Open Seminar of the Division of Advanced Genome Editing Therapy was held.

 Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential

Thesis

2025.03.03

Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential

 *Announcement* Presentation at the Lunch Meeting of the Research Institute and Center Conference

News

2025.02.26

*Announcement* Presentation at the Lunch Meeting of the Research Institute and Center Conference

 *Notice* Currently exhibiting at the Osaka-Kansai Expo pre-event!

News

2025.02.13

*Notice* Currently exhibiting at the Osaka-Kansai Expo pre-event!

 *Notice* UBE Corporation and UBE Corporation Commence Joint Research on Novel Combination Cancer Immunotherapy

News

2025.02.07

*Notice* UBE Corporation and UBE Corporation Commence Joint Research on Novel Combination Cancer Immunotherapy

 Cholesterol ensures ciliary polycystin-2 localization to prevent polycystic kidney disease

Thesis

2025.02.05

Cholesterol ensures ciliary polycystin-2 localization to prevent polycystic kidney disease

 Pharmacokinetics of Hydrogen During Hydrogen-Saturated Saline Infusion in Pigs

Thesis

2025.01.27

Pharmacokinetics of Hydrogen During Hydrogen-Saturated Saline Infusion in Pigs

 *Notice* We are challenging crowdfunding!

News

2025.01.21

*Notice* We are challenging crowdfunding!
Read More

About RICeD

Organization

Organization

 Member

Member

 Achievements

Achievements

Request for Donations to RICeD

We are promoting the development of cutting-edge cancer immunotherapy to cure many patients.
We are also working to extend the healthy lifespan of both humans and companion animals by applying the world’s first genome editing technology to the treatment of genetic diseases in companion animals and applying the results to human medicine,
We are also working to extend the healthy lifespan of both humans and companion animals by applying the results of our research to human medicine.We sincerely ask for your support to achieve these goals and to continue to promote the practical application of our research results in society.

Click here to donate

Instagram

ー Follow us! ー